Portal de Periódicos da CAPES

Cardiotrophin-1 in Heart Failure

2002; Lippincott Williams & Wilkins; Volume: 106; Issue: 12 Linguagem: Inglês

10.1161/01.cir.0000034024.61382.42

1524-4539

Michael R. Bristow, Carlin S. Long,

Cardiac Fibrosis and Remodeling

HomeCirculationVol. 106, No. 12Cardiotrophin-1 in Heart Failure Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBCardiotrophin-1 in Heart Failure Michael R. Bristow, MD, PhD and Carlin S. Long, MD Michael R. BristowMichael R. Bristow University of Colorado Health Sciences Center, Denver. and Carlin S. LongCarlin S. Long University of Colorado Health Sciences Center, Denver. Originally published17 Sep 2002https://doi.org/10.1161/01.CIR.0000034024.61382.42Circulation. 2002;106:1430–1432Cardiotrophin-1 (CT-1) is a 201 amino acid1 member of the interleukin (IL)-6 cytokine superfamily, which includes leukemia inhibitory factor (LIF), ciliary neurotrophic factor, IL-11, and oncostatin M.2 Cardiotrophin-1 was discovered by Pennica et al2 via expression cloning of mouse embryoid bodies, using a cardiac myocyte hypertrophy screen to identify positive clones. CT-1 has hypertrophic and cardioprotective properties and acts through LIF receptor β/glycoprotein 130 (gp130)-coupled signaling pathways. The LIF receptor binds CT-1, and then gp130 associates with the ligand-receptor complex and transduces the proximal signal. CT-1 intracellular signaling pathways include extracellular signal regulated kinases (ERK), mitogen activated protein (MAP) kinases, the janus kinase (JAK)/signal transducers and activators of transcription (STAT) system, and PI3-kinase/Akt. Downstream mediators of CT-1's cellular effects include multiple ERK-coupled transcription factors, STAT-3, nuclear factor-κB, and heat shock proteins 56, 70, and 90. Cardiac CT-1 expression is increased by hypoxia, where it protects cardiac myocytes from ischemic and reperfusion injury and apoptosis.See p 1442As described shortly after its discovery, CT-1 promotes cardiac myocyte hypertrophy by directing sarcomere assembly in series.3 At the ventricular structural level, in-series sarcomeric assembly leads to "eccentric" hypertrophy and chamber dilatation. Thus, increased myocardial expression of CT-1 immediately became a candidate for the molecular basis of pathological hypertrophy and remodeling in dilated cardiomyopathy phenotypes. The cardiac myocyte protective effects were also appreciated early in the investigation of CT-1's biological properties.4 Mice with genetic ablation of gp130 have hypoplastic hearts,5 which suggests a role for CT-1 or other IL-6–type cytokines in normal cardiac development. However, mice with ventricular myocyte-restricted knockout of gp130 using a ventricular myosin light chain 2 promoter that drives a Cre/lox recombination/knockout system from early in development have no cardiac abnormalities at birth,6 indicating that the hypoplastic heart phenotype of generalized gp130 knockout mice5 is likely secondary to hematologic or other noncardiac effects. Instead, cardiac myocyte-restricted knockout of gp130 in adult mice leads to left ventricular dilatation, myocyte apoptosis, and failure when the left ventricle is subjected to increased wall stress,6 highlighting the cardioprotective effects of gp130 signaling.The tissue expression of CT-1 is not confined to the fetal or adult heart. CT-1 is also expressed in adult skeletal muscle, ovary, colon, prostate, and testis and in fetal kidney and lung.2 When administered to mice intraperitoneally, CT-1 stimulates growth in the liver, kidney, and spleen and causes increases in platelet and red cell counts.7 CT-1 also has potent neuroprotective properties.8 Therefore, CT-1 likely has multiple, diverse biological functions.Mechanical stretch of cardiac myocytes increases the expression of CT-1 and activates the JAK/STAT pathway,9 providing a link from the biological properties of CT-1 to its potential role in remodeling in response to hemodynamic overload. Cardiac fibroblasts are major producers of CT-1, and non-myocytic production of CT-1 is probably important in the hypertrophic process.10 Myocardial gene expression of CT-1 is increased in heart failure animal models,11,12 and in humans with chronic heart failure, circulating levels of CT-1 are increased.13 Importantly, in animal models, CT-1 expression precedes the development of pathological hypertrophy.14 In model systems, norepinephrine markedly increases the expression of CT-1 in cardiac myocytes in vitro and in vivo, via a cAMP response element in the 5′ flanking region of the CT-1 gene.15 IL-6 superfamily cytokines induce at least some aspects of the myocardial fetal gene program16 that is a marker of pathological hypertrophy in both animal models and humans, and which likely plays a role in the development of the contractile dysfunction that accompanies pathological hypertrophy. Fetal gene induction in the failing human heart is under partial β1-adrenergic control,17 and so β-adrenergic stimulation of CT-1 gene expression is a candidate for the molecular mechanism of adrenergically-driven pathological remodeling in the failing human heart. CT-1 also engages in cross-talk with other mediators of hypertrophy, including angiotensin II18 and endothelin-1.16,19 In fact, the data of Sano et al18 suggest that substantial amounts of the cardiac hypertrophy produced by angiotensin II and endothelin-1 is mediated through increased expression of IL-6, LIF, and CT-1 in cardiac fibroblasts. Thus, myocardial CT-1 expression is a classic example of a cardiac compensatory mechanism that can be helpful or harmful. CT-1 signaling is anti-apoptotic and promotes hypertrophy, either of which may be beneficial, at least early in settings of hemodynamic overload. However, CT-1 also seems to play a role in the induction of the type of pathological hypertrophy and remodeling that is known to have an adverse effect on the natural history of left ventricular systolic dysfunction and chronic heart failure.In the current issue of Circulation, Zolk and colleagues20 report that chronically failing human left ventricles removed from subjects with either idiopathic dilated or ischemic cardiomyopathy express increased amounts of CT-1 mRNA (by 142%) and protein (by 68%). In view of the previously described elevated circulating levels in patients with chronic heart failure,13 the increased CT-1 expression in animal models,11,12 and the transmyocardial step-up of CT-1 in the human heart,21 these new findings are not surprising. In isolation, the obvious implication of this finding is that CT-1 is contributing to ventricular chamber hypertrophy and remodeling, as well as to protection against apoptosis in dilated cardiomyopathies. However, Zolk et al20 also measured protein abundance of several key components of the CT-1 signal transduction systems. Levels of gp130 protein were decreased by 34% while cognate mRNA abundance was increased by 91%, suggesting that gp130 protein turnover was increased by ligand-dependent internalization and degradation, with synthesis not keeping pace. In the study by Zolk et al,20 protein abundance of LIF receptor and suppressor of cytokine signaling (SOCS)-3, the latter an endogenous JAK inhibitor and suppressor of cytokine signaling, were not altered in the myopathic ventricles.In their interpretation of these findings, the authors20 speculate that desensitization of gp130 signaling "might contribute to deterioration of contractile function" in chronic heart failure by promoting apoptosis and ventricular dilatation as occurred in left ventricular pressure-overloaded cardiac myocyte-restricted gp130 knockout mice.5 However, Zolk et al20 did not assess the status of any downstream effectors of gp130, such as tyrosine phosphorylation of STAT-3, and so it is not clear whether the discordant changes in CT-1 and gp130 would produce a net increase or decrease in CT-1 signaling. Neither is it clear whether, if present, decreased CT-1/gp130signaling would be harmful. If the net effect of increased gp130 signaling is harmful within the context of an established dilated cardiomyopathy phenotype, as suggested by recent observations in cultured heart cells and a transgenic model investigating LIF activation of ERK5,22 then a reduction in signaling would be adaptive. Moreover, since different intracellular signaling pathways likely mediate the hypertrophic (JAK/STAT23 and/or ERK522 pathways) and anti-apoptotic (ERK1/2 pathways23) effects of CT-1, traffic through these respective signaling systems also depends on other cross-regulating influences. Thus, at present it is uncertain whether these newly described changes in the CT-1 signaling pathway20 constitute an adaptive or maladaptive response by the hypertrophied, failing human heart.Work such as the study by Zolk et al20 performed in explanted failing and nonfailing human hearts has provided valuable information and often novel insights into the pathobiology of chronic heart failure. Despite obvious limitations, which include being able to investigate only end stage disease and exposure of experimental material to multiple drugs and other potentially confounding variables, the phenotype of advanced dilated cardiomyopathy produces such overwhelming changes in gene expression and functional or structural biology that findings made in explanted human hearts have typically been reliable and reproducible. The major salutary features of this model can be appreciated in the article by Zolk et al.20 These are 1) confirmation of work previously performed in model systems and extension to the human setting (ie, increased CT-1 protein expression in failing myocardium), and 2) generation of new hypotheses, in this case that desensitization of CT-1 signaling maladaptively compromises a favorable, protective mechanism. Our experience has been that the greatest value of explanted human heart work is in hypothesis generation as a prelude to prospective studies in animal models and humans. As has been the case for therapeutic manipulation of other compensatory mechanisms in the failing heart, clinical investigation is ultimately required to determine whether a change observed in explanted failing hearts is adaptive or maladaptive. Thus, the question of the correct interpretation of the changes in CT-1/gp130 reported by Zolk et al20 will only be definitively answered by clinical trials that measure the efficacy and safety of yet to be developed modulators of CT-1 signaling and are conducted in patients with chronic heart failure.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Michael R. Bristow, MD, PhD, Division of Cardiology, University of Colorado, Health Sciences Center, 4200 East Ninth Ave, Campus Box B-139, Room BRB 123, Denver, CO 80262. References 1 Pennica D, Swanson TA, Shaw KJ, et al. Human cardiotrophin-1: protein and gene structure, biological and binding activities, and chromosomal localization. Cytokine. 1996; 8: 183–189.CrossrefMedlineGoogle Scholar2 Pennica D, King KL, Shaw KJ, et al. Expression cloning of cardiotrophin1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci U S A. 1995; 92: 1142–1146.CrossrefMedlineGoogle Scholar3 Wollert KC, Taga T, Saito M, et al. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem. 1996; 271: 9535–9545.CrossrefMedlineGoogle Scholar4 Sheng Z, Pennica D, Wood WI, et al. Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development. 1996; 122: 419–428.CrossrefMedlineGoogle Scholar5 Yoshida K, Taga T, Saito M, et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A. 1996; 93: 407–411.CrossrefMedlineGoogle Scholar6 Hirota H, Chen J, Betz UA, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999; 97: 189–198.CrossrefMedlineGoogle Scholar7 Jin H, Yang R, Keller GA, et al. In vivo effects of cardiotrophin-1. Cytokine. 1996; 8: 920–926.CrossrefMedlineGoogle Scholar8 Lesbordes JC, Bordet T, Haase G, et al. In vivo electrotransfer of the cardiotrophin-1 gene into skeletal muscle slows down progression of motor neuron degeneration in pmn mice. Hum Mol Genet. 2002; 11: 1615–1625.CrossrefMedlineGoogle Scholar9 Pan J, Fukuda K, Saito M, et al. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res. 1999; 84: 1127–1136.CrossrefMedlineGoogle Scholar10 Kuwahara K, Saito Y, Harada M, et al. Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation. 1999; 100: 1116–1124.CrossrefMedlineGoogle Scholar11 Jougasaki M, Tachibana I, Luchner A, et al. Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation. 2000; 101: 14–17.CrossrefMedlineGoogle Scholar12 Aoyama T, Takimoto Y, Pennica D, et al. Augmented expression of cardiotrophin-1 and its receptor component, gp130, in both left and right ventricles after myocardial infarction in the rat. J Mol Cell Cardiol. 2000; 32: 1821–1830.CrossrefMedlineGoogle Scholar13 Talwar S, Downie PF, Squire IB, et al. An immunoluminometric assay for cardiotrophin-1: a newly identified cytokine is present in normal human plasma and is increased in heart failure. Biochem Biophys Res Commun. 1999; 97: 567–571.Google Scholar14 Ishikawa M, Saito Y, Miyamoto Y, et al. A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. J Hypertens. 1999; 17: 807–816.CrossrefMedlineGoogle Scholar15 Funamoto M, Hishinuma S, Fujio Y, et al. Isolation and characterization of the murine cardiotrophin-1 gene: expression and norepinephrine-induced transcriptional activation. J Mol Cell Cardiol. 2000; 32: 1275–1284.CrossrefMedlineGoogle Scholar16 Saito S, Aikawa R, Shiojima I, et al. Endothelin-1 induces expression of fetal genes through the interleukin-6 family of cytokines in cardiac myocytes. FEBS Lett. 1999; 456: 103–107.CrossrefMedlineGoogle Scholar17 Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002; 346: 1357–1365.CrossrefMedlineGoogle Scholar18 Sano M, Fukuda K, Kodama H, et al. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem. 2000; 275: 29717–29723.CrossrefMedlineGoogle Scholar19 Tsuruda T, Jougasaki M, Boerrigter G, et al. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res. 2002; 90: 128–134.CrossrefMedlineGoogle Scholar20 Zolk O, Ng LL, O'Brien RJ, et al. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished gp130 receptor protein abundance. Circulation. 2002; 106: 1442-1446.LinkGoogle Scholar21 Asai S, Saito Y, Kuwahara K, et al. The heart is a source of circulating cardiotrophin-1 in humans. Biochem Biophys Res Commun. 2000; 279: 320–323.CrossrefMedlineGoogle Scholar22 Nicol RL, Frey N, Pearson G, et al. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 2001; 20: 2757–2767.CrossrefMedlineGoogle Scholar23 Sheng Z, Knowlton K, Chen J, et al. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway: divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem. 1997; 272: 5783–5791.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByZelt J, Chaudhary K, Cadete V, Mielniczuk L and Stewart D (2019) Medical Therapy for Heart Failure Associated With Pulmonary Hypertension, Circulation Research, 124:11, (1551-1567), Online publication date: 24-May-2019. Horn M and Trafford A (2016) Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2015.11.005, 93, (175-185), Online publication date: 1-Apr-2016. Zhou J, Gao J, Zhang X, Liu Y, Gu S, Zhang X, An X, Yan J, Xin Y and Su P (2015) microRNA-340-5p Functions Downstream of Cardiotrophin-1 to Regulate Cardiac Eccentric Hypertrophy and Heart Failure via Target Gene Dystrophin, International Heart Journal, 10.1536/ihj.14-386, 56:4, (454-458), . Dong Z, Wang Y, Li T, Zheng S, Kong Y, Lan Y, Guo J and Fu S (2014) p42/p44 mitogen-activated protein kinases inhibit atrial natriuretic peptide mRNA transcription in gp130-mediated hypertrophic ventricular myocytes, Asian Pacific Journal of Tropical Medicine, 10.1016/S1995-7645(14)60024-9, 7:3, (216-220), Online publication date: 1-Mar-2014. Lippi G and Cervellin G (2014) Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers, Critical Reviews in Clinical Laboratory Sciences, 10.3109/10408363.2013.863267, 51:1, (13-29), Online publication date: 1-Feb-2014. Sánchez-Millán P, Cabeza-Lainez P, Castillo-Ortiz J, Pérez-Navarro M, Sancho-Jaldón M, Lagares-Carballo M, Otero-Chulián E and Vázquez-García R (2013) Niveles séricos de cardiotrofina-1 y su relación con la morfología septal en la miocardiopatía hipertrófica, Cardiocore, 10.1016/j.carcor.2012.08.003, 48:1, (41-43), Online publication date: 1-Jan-2013. Fukuhara S and Leitman I (2013) Cardiotrophin-1, an antiinflammatory cytokine; is there a therapeutic role in orthotopic liver transplantation?, Journal of Surgical Research, 10.1016/j.jss.2012.08.003, 185:1, (e63-e65), Online publication date: 1-Nov-2013. Bonura F, Di Lisi D, Novo S and D'Alessandro N (2011) Timely Recognition of Cardiovascular Toxicity by Anticancer Agents: A Common Objective of the Pharmacologist, Oncologist and Cardiologist, Cardiovascular Toxicology, 10.1007/s12012-011-9141-z, 12:2, (93-107), Online publication date: 1-Jun-2012. Sanz-Rosa D (2011) Los receptores β adrenérgicos en la enfermedad cardiovascular, Hipertensión y Riesgo Vascular, 10.1016/j.hipert.2011.02.002, 28:2, (55-62), Online publication date: 1-Mar-2011. Liu J, Shen Q and Wu Y (2008) Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway, Life Sciences, 10.1016/j.lfs.2008.02.012, 82:19-20, (991-996), Online publication date: 1-May-2008. TROUGHTON R, RITZEMA-CARTER J and NICHOLLS M (2008) Role of Neurohormones Diastology, 10.1016/B978-1-4160-3754-5.50033-0, (345-366), . Jessani S and Lip G (2006) Death or Heart Failure Post Acute Myocardial Infarction? The Role of Cardiac Biomarkers, Journal of Cardiac Failure, 10.1016/j.cardfail.2006.07.004, 12:8, (641-643), Online publication date: 1-Oct-2006. Wilson Tang W and Francis G (2005) Neurohormonal Upregulation in Heart Failure, Heart Failure Clinics, 10.1016/j.hfc.2004.11.002, 1:1, (1-9), Online publication date: 1-Apr-2005. Bril A and Feuerstein G (2003) The role of IL-6 and related cytokines in myocardial remodeling and inflammation – implication for cardiac hypertrophy and heart failure Inflammation and Cardiac Diseases, 10.1007/978-3-0348-8047-3_7, (111-127), . Ng X, Huang Y, Chen H, Burnett J, Boey F, Venkatraman S and Engler A (2013) Cenderitide-Eluting Film for Potential Cardiac Patch Applications, PLoS ONE, 10.1371/journal.pone.0068346, 8:7, (e68346) September 17, 2002Vol 106, Issue 12 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000034024.61382.42PMID: 12234941 Originally publishedSeptember 17, 2002 Keywordsheart failuresignal transductionhypertrophyEditorialsPDF download Advertisement